The Buzz, Issue #2 is now available! Check out this month’s selection of new publications clinically relevant to Canadian allergists, immunologists and dermatologists.

The Buzz Issue #2, April edition, was sent to all HIVE members by email on Monday, March 29, and can be accessed online here. This edition covers:

  • The allergists’ perspective on anaphylaxis risk with SARS-CoV-2 vaccines
  • Emerging biologics for chronic spontaneous urticaria
  • Predictors of response and non-response in chronic spontaneous urticaria
  • Real-world analysis of omalizumab in chronic inducible urticaria
  • Quantifying peanut allergen thresholds in Canadian children and young adults

To view all issues of The Buzz, go to thehivecommunity.org/the-buzz

Introducing “The Buzz”, a monthly feature of the HIVE community where recent articles are selected and summarized for clinical relevance to Canadian allergists, immunologists and dermatologists

We’re delighted to introduce a new feature of the HIVE community – The Buzz!

The Buzz is a monthly selection of new publications clinically relevant to the HIVE community of Canadian allergists, immunologists and dermatologists.

The Buzz will be sent to all HIVE members by email each month, with highlights in the weekly HIVE email digests. View all issues of The Buzz online here.